Form 4: Supernus Pharmaceuticals Executive Awarded Performance Share Units

Frank Mottola, SVP at Supernus Pharmaceuticals, was awarded 2,625 Performance Share Units on February 17, 2025, a portion of which vested upon achievement of individual performance objectives.

Summary

• Frank Mottola, SVP at Supernus Pharmaceuticals, filed a Form 4 on February 19, 2025, reporting changes in beneficial ownership.
• On February 17, 2025, Mottola was awarded 2,625 Performance Share Units.
• These units vest upon the achievement of individual performance objectives established on June 24, 2024.
• Mottola directly owns 8,451 shares of Supernus Pharmaceuticals common stock.
• Following the reported transaction, Mottola beneficially owns 2,625 derivative securities in the form of Performance Share Units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The awarding of performance share units is a standard practice and suggests confidence in the executive's ability to meet performance objectives. No negative information is present.

Positives

• The awarding of Performance Share Units to a key executive suggests the company is incentivizing performance and aligning executive interests with shareholder value.

Future Outlook

The vesting of the Performance Share Units is contingent on the achievement of individual performance objectives, suggesting a focus on future performance.

Industry Context

Executive compensation through equity-based awards like Performance Share Units is a common practice in the pharmaceutical industry to align management's interests with long-term shareholder value and company performance.

Stakeholder Impact

• Shareholders may view the awarding of Performance Share Units positively, as it incentivizes management to achieve performance goals that benefit the company's value.

Key Dates

Keywords

Form 4, Supernus Pharmaceuticals, Performance Share Units, Beneficial Ownership, Executive Compensation, Mottola, SUPN